Takeda files for once-daily pioglitazone combo in EU
This article was originally published in Scrip
Takedahas made a filing with the EMEAthrough the centralised procedure for the European approval of a once-daily formulation of Competact, its pioglitazone plus metformin combination therapy for type 2 diabetes. A twice-daily version of the fixed-dose product, containing 15mg pioglitazone and 850mg metformin, is already on the market in several European countries, for patients insufficiently controlled on their maximum dose of metformin alone. A similar once-daily combination of the two ingredients was filed in the US (as ACTOplus met XR) in March 2006, but has yet to be approved.